Cyclacel Pharmaceuticals, Inc.
CYCC
$7.99
-$0.01-0.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -87.50% | -96.88% | -89.76% | -80.98% | -78.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -87.50% | -96.88% | -89.76% | -80.98% | -78.55% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -87.50% | -96.88% | -89.76% | -80.98% | -78.55% |
| SG&A Expenses | 13.76% | 20.25% | -19.67% | -9.56% | -9.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.89% | -44.64% | -53.44% | -46.77% | -29.89% |
| Operating Income | 48.73% | 43.59% | 52.84% | 46.31% | 29.26% |
| Income Before Tax | 73.37% | 65.79% | 53.06% | 45.15% | 27.97% |
| Income Tax Expenses | 134.52% | 118.88% | 73.90% | 42.29% | 36.55% |
| Earnings from Continuing Operations | 63.40% | 57.62% | 50.29% | 45.63% | 26.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.40% | 57.62% | 50.29% | 45.63% | 26.34% |
| EBIT | 48.73% | 43.59% | 52.84% | 46.31% | 29.26% |
| EBITDA | 48.70% | 43.56% | 52.80% | 46.30% | 29.25% |
| EPS Basic | -46.97% | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -46.97% | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 9,408.99% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.12% | -- | -- | 0.54% | 0.32% |